Skip to content

Study · Randomized controlled trial · 2025

8 results

The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.

Heerspink HJL, Lu Z, Du Y, Duffin KL, Coskun T, Haupt A, Hartman ML

Kidney international reports2 Apr 2025Cited by 13 (Europe PMC)

PMID40630318 (opens in a new tab)PMCIDPMC12231004 (opens in a new tab)DOI10.1016/j.ekir.2025.03.049 (opens in a new tab)PepBankPUB-40630318
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, retatrutide 12 mg reduced urine albumin-to-creatinine ratio more than placebo at 36 weeks.

    In plain wordsIn adults with type 2 diabetes, retatrutide 12 mg lowered a urine kidney marker (UACR) more than placebo.

    Peptide
    Retatrutide
    Outcome
    DecreaseUACR change vs placebo at week 36 (T2D)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    12 mg · 36 weeksAs given in this study (human).

    Measurements

    UACR difference vs placebo
    −37%
    retatrutide 12 mg, T2D, week 36

    Source sentences

    Summary
    retatrutide 12 mg was associated with reduced UACR compared with placebo at 36 weeks by -37.0% (95% CI: -57.3 to -7.0)
    2 context sentences
    Summary · context
    A post hoc analysis of 2 retatrutide studies (dose range: 0.5-12 mg) was performed in participants (estimated glomerular filtration rate [eGFR] ≥ 45 ml/min per 1.73 m2) with T2D (n = 281) and with overweight or obesity without T2D (n = 338).
    Summary · context
    Both studies were placebo-controlled; the T2D study included dulaglutide 1.5 mg as an active comparator.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, eGFR with retatrutide 12 mg was unchanged compared with placebo at 36 weeks.

    In plain wordsIn adults with type 2 diabetes, kidney filtration (eGFR) with retatrutide 12 mg did not differ from placebo.

    Peptide
    Retatrutide
    Outcome
    No significant changeeGFR vs placebo at week 36 (T2D)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    12 mg · 36 weeksAs given in this study (human).

    Source sentences

    Summary
    eGFR was unchanged compared with placebo.
    2 context sentences
    Summary · context
    A post hoc analysis of 2 retatrutide studies (dose range: 0.5-12 mg) was performed in participants (estimated glomerular filtration rate [eGFR] ≥ 45 ml/min per 1.73 m2) with T2D (n = 281) and with overweight or obesity without T2D (n = 338).
    Summary · context
    Both studies were placebo-controlled; the T2D study included dulaglutide 1.5 mg as an active comparator.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity without T2D, retatrutide 8 mg decreased UACR compared with placebo at 48 weeks.

    In plain wordsIn adults with overweight or obesity, retatrutide 8 mg lowered a urine kidney marker (UACR) compared with placebo.

    Peptide
    Retatrutide
    Outcome
    DecreaseUACR change vs placebo at week 48 (obesity), 8 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    8 mg · 48 weeksAs given in this study (human).

    Measurements

    UACR difference vs placebo
    −28%
    retatrutide 8 mg, week 48

    Source sentences

    Summary
    retatrutide 8 mg and 12 mg, compared with placebo at 48 weeks, was associated with decreased UACR by -28.0% (95% CI: -46.0 to -4.1) and -31.5% (95% CI: -49.3 to -7.4)
    2 context sentences
    Summary · context
    A post hoc analysis of 2 retatrutide studies (dose range: 0.5-12 mg) was performed in participants (estimated glomerular filtration rate [eGFR] ≥ 45 ml/min per 1.73 m2) with T2D (n = 281) and with overweight or obesity without T2D (n = 338).
    Summary · context
    Both studies were placebo-controlled; the T2D study included dulaglutide 1.5 mg as an active comparator.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity without T2D, retatrutide 12 mg decreased UACR compared with placebo at 48 weeks.

    In plain wordsIn adults with overweight or obesity, retatrutide 12 mg lowered a urine kidney marker (UACR) compared with placebo.

    Peptide
    Retatrutide
    Outcome
    DecreaseUACR change vs placebo at week 48 (obesity), 12 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    12 mg · 48 weeksAs given in this study (human).

    Measurements

    UACR difference vs placebo
    −31.5%
    retatrutide 12 mg, week 48

    Source sentences

    Summary
    retatrutide 8 mg and 12 mg, compared with placebo at 48 weeks, was associated with decreased UACR by -28.0% (95% CI: -46.0 to -4.1) and -31.5% (95% CI: -49.3 to -7.4)
    2 context sentences
    Summary · context
    A post hoc analysis of 2 retatrutide studies (dose range: 0.5-12 mg) was performed in participants (estimated glomerular filtration rate [eGFR] ≥ 45 ml/min per 1.73 m2) with T2D (n = 281) and with overweight or obesity without T2D (n = 338).
    Summary · context
    Both studies were placebo-controlled; the T2D study included dulaglutide 1.5 mg as an active comparator.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity without T2D, retatrutide 8 mg increased creatinine-derived eGFR compared with placebo at 48 weeks.

    In plain wordsIn adults with overweight or obesity, retatrutide 8 mg raised kidney filtration (eGFR) compared with placebo.

    Peptide
    Retatrutide
    Outcome
    IncreaseeGFR (creatinine) vs placebo at week 48, 8 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    8 mg · 48 weeksAs given in this study (human).

    Measurements

    eGFR (creatinine) difference vs placebo
    5.3 ml/min per 1.73 m2
    retatrutide 8 mg, week 48

    Source sentences

    Summary
    retatrutide 8 mg and 12 mg, compared with placebo at 48 weeks, was associated with decreased UACR by -28.0% (95% CI: -46.0 to -4.1) and -31.5% (95% CI: -49.3 to -7.4), respectively, and with increased eGFR derived from creatinine by 5.3 ml/min per 1.73 m2 (95% CI: 1.9-8.7) and 8.5 ml/min…
    2 context sentences
    Summary · context
    A post hoc analysis of 2 retatrutide studies (dose range: 0.5-12 mg) was performed in participants (estimated glomerular filtration rate [eGFR] ≥ 45 ml/min per 1.73 m2) with T2D (n = 281) and with overweight or obesity without T2D (n = 338).
    Summary · context
    Both studies were placebo-controlled; the T2D study included dulaglutide 1.5 mg as an active comparator.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity without T2D, retatrutide 12 mg increased creatinine-derived eGFR compared with placebo at 48 weeks.

    In plain wordsIn adults with overweight or obesity, retatrutide 12 mg raised kidney filtration (eGFR) compared with placebo.

    Peptide
    Retatrutide
    Outcome
    IncreaseeGFR (creatinine) vs placebo at week 48, 12 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    12 mg · 48 weeksAs given in this study (human).

    Measurements

    eGFR (creatinine) difference vs placebo
    8.5 ml/min per 1.73 m2
    retatrutide 12 mg, week 48

    Source sentences

    Summary
    retatrutide 8 mg and 12 mg, compared with placebo at 48 weeks, was associated with decreased UACR by -28.0% (95% CI: -46.0 to -4.1) and -31.5% (95% CI: -49.3 to -7.4), respectively, and with increased eGFR derived from creatinine by 5.3 ml/min per 1.73 m2 (95% CI: 1.9-8.7) and 8.5 ml/min…
    2 context sentences
    Summary · context
    A post hoc analysis of 2 retatrutide studies (dose range: 0.5-12 mg) was performed in participants (estimated glomerular filtration rate [eGFR] ≥ 45 ml/min per 1.73 m2) with T2D (n = 281) and with overweight or obesity without T2D (n = 338).
    Summary · context
    Both studies were placebo-controlled; the T2D study included dulaglutide 1.5 mg as an active comparator.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, retatrutide similarly increased eGFR derived from cystatin C.

    In plain wordsIn adults with overweight or obesity, retatrutide similarly raised a second kidney filtration estimate (eGFR from cystatin C).

    Peptide
    Retatrutide
    Outcome
    IncreaseeGFR derived from cystatin C
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Similar increases in eGFR derived from cystatin C and combined creatinine-cystatin C eGFR were observed.
    2 context sentences
    Summary · context
    A post hoc analysis of 2 retatrutide studies (dose range: 0.5-12 mg) was performed in participants (estimated glomerular filtration rate [eGFR] ≥ 45 ml/min per 1.73 m2) with T2D (n = 281) and with overweight or obesity without T2D (n = 338).
    Summary · context
    Both studies were placebo-controlled; the T2D study included dulaglutide 1.5 mg as an active comparator.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, retatrutide similarly increased the combined creatinine-cystatin C eGFR.

    In plain wordsIn adults with overweight or obesity, retatrutide similarly raised a combined kidney filtration estimate (eGFR).

    Peptide
    Retatrutide
    Outcome
    IncreaseCombined creatinine-cystatin C eGFR
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Similar increases in eGFR derived from cystatin C and combined creatinine-cystatin C eGFR were observed.
    2 context sentences
    Summary · context
    A post hoc analysis of 2 retatrutide studies (dose range: 0.5-12 mg) was performed in participants (estimated glomerular filtration rate [eGFR] ≥ 45 ml/min per 1.73 m2) with T2D (n = 281) and with overweight or obesity without T2D (n = 338).
    Summary · context
    Both studies were placebo-controlled; the T2D study included dulaglutide 1.5 mg as an active comparator.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.